The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer

Basit Öğe Kaydı
dc.authorid0000-0002-0077-6971
dc.authorid0000-0002-0443-6966
dc.authorid0000-0001-7934-7039
dc.authorid0000-0003-2715-4002
dc.authorid0000-0002-7685-2766
dc.authorid0000-0002-9452-9276
dc.authorid0000-0003-0128-6947
dc.authorid0000-0002-5823-1704
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorÖven, Bala Başak
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorÇakır, Tansel
dc.contributor.authorBasım, Pelin
dc.contributor.authorÇakır, Aslı
dc.contributor.authorKutlu, Yasin
dc.contributor.authorHamdard, Jamshid
dc.date.accessioned2022-11-10T07:24:11Z
dc.date.available2022-11-10T07:24:11Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Genel Cerrahi Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractPurpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy for assessing the efficacy of NAC has not been established yet, but several studies have shown that 18F-FDG PET/CT is a potential imaging tool for assessing pCR. The aim of this study is to investigate the merits of 18F-FDG PET/CT imaging in predicting pCR in both axillary and breast tissue and to establish a threshold maximum standard uptake value (SUVmax) for predicting the response after completion of NAC. Methods: A total of 186 LABC patients, treated with an NAC regimen according to tumor subtype, were retrospectively analyzed in this study. All patients underwent 18F-FDG PET/CT imaging before and after completion of NAC. PET parameters were measured in the most FDG avid breast tissue and axillary lymph nodes. We analyzed the correlation between the tumor SUVmax of the PET/CT response and the pCR after surgery. DFS was also evaluated with respect to pCR. Results: Higher pCR rates were significantly associated with a higher tumor grade, an initial Ki-67 >= 20% (p = 0.03 and p = 0.003, respectively), a triple-negative subtype (32.9%), and a human epidermal growth factor receptor 2 (HER-2)-positive subtype (24.7%) (p < 0.001). There was a significant correlation between the pCR and a complete response in 18F-FDG PET/CT (p < 0.001). The overall sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 18F-FDG PET/CT to determine the pCR after NAC were 100%, 72.2%, 85%, 75.2%, and 100%, respectively. We demonstrated a 1.1 cutoff SUVmax for breast tumors after NAC (OR: 3.94, 95% CI: 1.14-5.05, p = 0.004), the 18F-FDG PET/CT response to NAC (OR: 0.50, 95% CI: 0.25-0.99, p = 0.003), and the molecular subtype of breast tumors (OR: 0.58, 95% CI: 0.38-0.88, p = 0.011). Conclusion: Our results confirm that 18F-FDG PET/CT is a useful method for predicting the NAC response in LABC.
dc.identifier.citationGöktaş Aydın, S., Bilici, A., Ölmez, Ö. F., Öven, B. B., Açıkgöz, Ö., Çakır, T. ... Hamdard, J. (2022). The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer. Breast Care, 17(5), 470-479. https://doi.org/10.1159/000524446
dc.identifier.doi10.1159/000524446
dc.identifier.endpage479
dc.identifier.issn1661-3791
dc.identifier.issn1661-3805
dc.identifier.issue5
dc.identifier.pmid36684400
dc.identifier.scopus2-s2.0-85140837793
dc.identifier.scopusqualityQ1
dc.identifier.startpage470
dc.identifier.urihttps://doi.org/10.1159/000524446
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9947
dc.identifier.volume17
dc.identifier.wos000875519700004en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorAçıkgöz, Özgür
dc.institutionauthorÇakır, Tansel
dc.institutionauthorBasım, Pelin
dc.institutionauthorÇakır, Aslı
dc.institutionauthorKutlu, Yasin
dc.institutionauthorHamdard, Jamshid
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofBreast Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subject18F-FDG PET/CT
dc.subjectBreast Cancer
dc.subjectNeoadjuvant Chemotherapy
dc.subjectPrognostic Factors
dc.subjectSurvival
dc.titleThe role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu